Shots:
- LCB will be eligible to receive up front and milestones along with royalties & is eligible to receive a prespecified percentage of any sublicensing income received by Antengene, if an option is exercised
- Antengene to get an exclusive option to license global rights for the development and commercialization of the ADC candidates. Both companies will jointly evaluate ADC candidates by using Antengene’s Abs and LCB’s ADC technology platform
- The agreement will combine Antengene’s expertise in oncology with LCB’s clinically validated ADC technology platform to accelerate the development of new therapies
Click here to read full press release/ article | Ref: PR Newswire | Image: Antengene
The post Antengene Enters into a Research Collaboration & License Option Agreement with LegoChem Biosciences for Antibody-Drug Conjugate Candidates first appeared on PharmaShots.
